Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions.


Journal

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
ISSN: 1718-4304
Titre abrégé: Perit Dial Int
Pays: United States
ID NLM: 8904033

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 14 2 2020
medline: 25 11 2021
entrez: 14 2 2020
Statut: ppublish

Résumé

Peritonitis is a common and serious complication of peritoneal dialysis (PD). PD-associated peritonitis (PDAP) caused by A total of 27 PD bags (3 PD bags for each type of PD solution including Dianeal®, Extraneal®, Balance® and Physioneal® PD bags) containing C/T were prepared and stored at 25°C for 6 h, followed by 4°C for 168 h and then 37°C for 12 h. An aliquot from each PD bag was withdrawn, and the concentration of C/T before (0 h) and after predefined time points was determined using a stability-indicating high-performance liquid chromatography assay. Samples were also assessed for pH, colour change and particulate matter immediately after preparation and on each day of analysis. C/T retained more than 97% of their initial concentration when stored at 25°C for 6 h followed by storage at 4°C for 168 h and then at 37°C for 12 h. Particle formation was not detected at any time under the tested storage conditions. The pH and colour remained essentially unchanged throughout the study. These results provide a platform for clinical studies to determine the safety and therapeutic efficacy of intraperitoneal C/T for the treatment of PDAP caused by resistant

Sections du résumé

BACKGROUND
Peritonitis is a common and serious complication of peritoneal dialysis (PD). PD-associated peritonitis (PDAP) caused by
METHODS
A total of 27 PD bags (3 PD bags for each type of PD solution including Dianeal®, Extraneal®, Balance® and Physioneal® PD bags) containing C/T were prepared and stored at 25°C for 6 h, followed by 4°C for 168 h and then 37°C for 12 h. An aliquot from each PD bag was withdrawn, and the concentration of C/T before (0 h) and after predefined time points was determined using a stability-indicating high-performance liquid chromatography assay. Samples were also assessed for pH, colour change and particulate matter immediately after preparation and on each day of analysis.
RESULTS
C/T retained more than 97% of their initial concentration when stored at 25°C for 6 h followed by storage at 4°C for 168 h and then at 37°C for 12 h. Particle formation was not detected at any time under the tested storage conditions. The pH and colour remained essentially unchanged throughout the study.
CONCLUSIONS
These results provide a platform for clinical studies to determine the safety and therapeutic efficacy of intraperitoneal C/T for the treatment of PDAP caused by resistant

Identifiants

pubmed: 32052692
doi: 10.1177/0896860820902590
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cephalosporins 0
Dialysis Solutions 0
ceftolozane 37A4IES95Q
Ceftazidime 9M416Z9QNR
Tazobactam SE10G96M8W

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

470-476

Auteurs

Harmanjeet Harmanjeet (H)

Division of Pharmacy, School of Medicine, 3925University of Tasmania, Australia.

Het Jani (H)

Division of Pharmacy, School of Medicine, 3925University of Tasmania, Australia.

Syed Tabish R Zaidi (STR)

Division of Pharmacy, School of Medicine, 3925University of Tasmania, Australia.
School of Healthcare, University of Leeds, UK.

Troy Wanandy (T)

Division of Pharmacy, School of Medicine, 3925University of Tasmania, Australia.
Department of Pharmacy, 497744Royal Hobart Hospital, Australia.

Ronald L Castelino (RL)

Division of Pharmacy, School of Medicine, 3925University of Tasmania, Australia.
School of Nursing, 4334University of Sydney, Australia.
Peritoneal Dialysis Unit, Regional Dialysis Centre, Blacktown Hospital, Australia.

Kamal Sud (K)

Peritoneal Dialysis Unit, Regional Dialysis Centre, Blacktown Hospital, Australia.
Department of Renal Medicine, Nepean Hospital and Nepean Clinical School, 4334The University of Sydney, Australia.

Gregory M Peterson (GM)

Division of Pharmacy, School of Medicine, 3925University of Tasmania, Australia.

Rahul P Patel (RP)

Division of Pharmacy, School of Medicine, 3925University of Tasmania, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH